Revised as of July 25, 2023 Yonago Acta Medica Editorial Committee Tottori University Medical Press Yonago, Japan

# Yonago Acta Medica Instructions for Authors 2023

# Contents

P 2 Overview

# **Manuscript Style**

P 3	<b>§ 1</b>	Paper
P 3	§ 2	Format
P 3	§ 3	Manuscript Structure
P 3	<b>§4</b>	Title page
P 3	§ 5	Abstract page
P 4	§ 6	Text pages
P 5	§7	Acknowledgments
P 5	§ 8	Conflict of interest
P 5	§ 9	References
P 6	<b>§10</b>	Tables
P 6	<b>§11</b>	Legends for figures
P 6	<b>§12</b>	Figures
P 7	<b>§13</b>	Abbreviations
P 8	<b>§14</b>	E-text and online submission

# Appendices

P9 Table 1	. List of abbreviations
------------	-------------------------

- P 9 Table 2. SI prefixes, symbols & factors
- P9 Table 3. SI and related units
- P 10 Table 4. Statistical symbols
- P 10 Table 5. Japanese selections from the list of journal indexed for PubMed users
- P 11 International Committee of Medical Journal Editors (ICMJE) Uniform Requirements for Manuscripts (URM) Submitted to Biomedical Journals: Sample references
- P14 ICMJE Form for Disclosure of Potential Conflicts of Interest (Abstract form)
- P14 Code of Ethics

# Overview

- Yonago Acta Medica is published four times a year by the Tottori University Medical Press. As a general rule, its contributors are limited to researchers of the Tottori University and the Tottori University Hospital. However, researchers from outside the university community mentioned above may also submit papers, provided they receive a recommendation from professors, associate professors, junior associate professors within the university, or members of the Editorial Committee of Yonago Acta Medica. The subject areas encompass the following fields: molecular/cell biology, biochemistry, basic medicine, clinical medicine, veterinary medicine, clinical nutrition and food sciences, medical engineering, nursing sciences, laboratory medicine, clinical psychology, and medical education.
- 2) Deadlines for submissions and publication months are as follows:

Issue	Scheduled publica	ation month Submission period
1	February	All year round
2	May	(Excludes thesis intended
3	August	for degree application*)
4	November	

\*A deadline has already been set for the thesis for the doctoral degree application. For the deadline information, please refer to the campus e-mail regarding the submission process, which is delivered by the editorial office, or contact us directly.

- 3) Manuscripts must not have been previously published by another journal. Do not submit any manuscript scheduled for publication or currently submitted to a different publisher. Works published in our journal (including manuscripts currently submitted for review) may not be reproduced in other publications without our authorization.
- 4) For our code of ethics, please see page 14.
- 5) Contributors must conduct a self-check for the status of conflicts of interest (COI) regarding the paper via the "Form for Disclosure of Potential Conflicts of Interest," provided by International Committee of Medical Journal Editors (ICMJE). The form can be accessed and downloaded through the following link:

http://www.icmje.org/conflicts-of-interest/

For an abstract of the form, see page 14. If, after verification, it is confirmed that there are no conflicts of interest in all the question items, please state the result in your cover letter. If, on the other hand, any conflicts of interest are found, this should also be stated in the cover letter and the completed above-mentioned form should be additionally submitted to Yonago Acta Medica.

- 6) Articles should be proofread by native speakers of English before submission. Diagram titles and legends, as well as any other text, also need to be proofread.
- 7) Manuscripts should be submitted in digital format to the editorial office. The submission form and a cover letter addressed to the editor-in-chief, in which the new findings of the paper are detailed, must be submitted as well. Those documents may be attached to an e-mail or submitted through a portable medium such as a compact disc or a USB flash drive.
- 8) Papers are categorized as follows: review articles (up to 6,000 words), original articles (up to 5,000 words), patient reports (up to 4,000 words), and short communications (up to 1,200 words.) Text in abstracts, references, and diagrams is not included in the word count. Short communications should not include more than one figure and one table, respectively.
- 9) Following peer review and revision, the final version of manuscripts will be submitted to an English-language editor designated by the editorial committee.
- 10) The copyrights and publication rights (including online publication) of the manuscripts belong to the Tottori University Medical Press. The management of the copyrights of Yonago Acta Medica is entrusted to the Japan Academic Association For Copyright Clearance (JAC). Administration fees of JAC shall be deducted from the royalties and the remainder shall be considered the revenue of the Tottori University Medical Press. To consent to these terms, contributors must sign the copyright transfer document (page 2 of the submission form). All co-authors must also sign the form.

- As a general rule, proofreading is limited to two times and is performed within 48 hours. Do not make corrections to the manuscript at the proofreading stage.
- 12) Necessary expenses will be charged.
- 13) In the case of theses intended for Ph.D. degree application, the supervisor for the applicant should affix his/her seal on the top right of the submission form. Administrative information should be entered on the submission form. The form can be found on and downloaded from the Tottori University Medical Library site. (http://www.lib.tottori-u. ac.jp/yam/file5-1.html)

# Manuscript Style

# §1 Paper

- 1) A4 or Letter size.
- 2) 2.5 cm margin on all sides.
- 3) About 60 characters per line and 25 to 27 lines and about 300 words per page is standard. The number of words per page may be increased.
- 4) Pagination must be included in the upper right corner from page 2. Refer to the header style of this page.

# § 2 Format

- 1) Use 10 or 12 point font.
- Type in the European typing style. Fonts such as Times New Roman, Arial, etc. are preferable.
   \*Do not use Japanese fonts, including symbols.

# § 3 Manuscript Structure

For original articles, follow the structure below. Insert a page break after each section and add pagination.

1)	Title page	$\rightarrow$ § 4
2)	ABSTRACT, Key words	$\rightarrow$ § 5
3)	TEXT	$\rightarrow$ § 6
4)	Acknowledgments	$\rightarrow$ § 7
5)	Conflict of interest	$\rightarrow$ § 8
6)	REFERENCES	$\rightarrow$ § 9
7)	Tables	$\rightarrow$ § 10
8)	Legends for figures	$\rightarrow$ § 11
9)	Figures	$\rightarrow$ § 12

# § 4 Title page

Follow the structure below.

- 1) Title. For subtitles, insert a colon after the title and type on the same line. (Do not use a dash.)
- 2) Author. Type full names as in the following example. (Do not include degrees, titles, etc.)

Ex: Taro Tottori, Hanako Yonago and Jiro Kurayoshi

3) Affiliation. If different authors have different affiliations, use footnote symbols in the following order for each.

\*, †, ‡, §, ||, ¶, \*\*, ††, ‡‡, §§, ||||, ¶¶, . . .

Write organization names, city names, and postal codes. Do not include street numbers and prefectures. [Example]

Taro Yamada\* and Jiro Suzuki\*

\*Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan and †Division of Organ Pathology, Department of Pathology, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan

- 4) Corresponding author. Next to the full name, write titles (MD, PhD, etc.) and e-mail addresses.
- 5) Running title. Must be within 50 characters.

\*Abbreviations (including author-specific terms) may be used. First letter should be capitalized.

6) Abbreviations. List of abbreviations used by the author. (See p. 8, section 13.5 for reference)

# **5.1 ABSTRACT**

- Original articles should use the "structured abstract" format (Divided according to the following structure: Background, Methods, Results, Conclusion.) For other categorized articles, use the "one paragraph" structure.
- 2) Short communications should be no longer than 150 words. Others should be no longer than 300 words.
- 3) Abbreviations and scientific notation should be avoided as much as possible in abstracts.
- 4) Do not directly cite diagrams or references.

# 5.2 Key words

1) Arrange up to 5 items in alphabetical order without using abbreviations and separate them with semicolons (;). Use lowercase letters (except for proper nouns and proper adjectives).

[Example]: Key words: electrooculography; magnetic resonance imaging; streptozotocin

2) Keywords should be selected from MEDLINE/Pubmed entries and/or Medical Subject Headings (MeSH). To check the MeSH terms, go to PubMed and search the MeSH Database. If using italic or Greek characters, review and align with the MeSH style recommendations. Also consult MeSH for keyword superscripts/subscripts.

PubMed Services>MeSH Database [to find MeSH Terms]www.ncbi.nlm.nih.gov/entrez/query.fcgi > www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=mesh

MeSH is NLM's controlled vocabulary used for indexing articles for MEDLINE/PubMed [NLM =United States' National Library of Medicine] ★ A dedicated link to PubMed for Tottori University can be found on the Tottori University Library site. (http://www.lib.tottori-u.ac.jp/medical.html/)

# § 6 Text pages

# 6.1 Text structure

For original articles, follow the structure below.

- 1) INTRODUCTION \*Do not use headings for introductions.
- 2) MATERIALS AND METHODS (SUBJECTS AND METHODS or EXPERIMENTAL PROCEDURES are also acceptable.)
- 3) RESULTS
- 4) DISCUSSION (or RESULTS AND DISCUSSION)

For patient reports, follow the structure below.

- 1) INTRODUCTION \*Do not use headings for introductions.
- 2) PATIENT REPORT
- 3) (DISCUSSION) \*There may not be a discussion section.

# 6.2 Subheading

Divide MATERIALS AND METHODS and RESULTS into sections with subheadings. Do not number the subheadings. In the DISCUSSION, keep the text concise without dividing it into sections.

# 6.3 Style guide

- 1) Alignment
  - Do not justify text on the right.
- 2) Space

Within the text, leave a half-width space between words, between numbers and units, after punctuation, etc. \*Exceptions\*: % and ° (angles) should be typed without space next to the number.

## 3) Hyphens

- a. Do not split words at the end of a line. Exception: anti-
- b. Latin terms used as adjectives should not be hyphenated.

Example: in vitro methods; post hoc hypothesis

c. Use an en-dash (-) to express range. There should be no space between the en-dash and the values.

Example: 5-10 mL; 200-800 pg/mL

d. Use an en-dash (-) for the minus symbol.

# 4) Numbers

- a. Use Arabic numerals before units.
- b. When a number appears at the beginning of a sentence, spell both numbers and units. Do not start sentences with Arabic numerals. Figure descriptions may start with Arabic numerals.
- c. As a general rule, numbers are represented using Arabic numerals. However, we respect the style of the author for number use. Take care not to mix Arabic numerals and spelled numbers.

Example : "1 patient" and "one patient" should not be mixed.

d. For numbered enumeration within the text, use lower-case roman numerals. Roman numerals combine the letters i, v, x, etc. [Example]: i); ii); ... iv); v); ... ix); x) ....

# 5) Brackets

- a. Bracket types should be used in this order: {...[....]...]...}. The same type should not be used twice in a row. Incorrect example: (....(...)...)
- b. Quotations in parentheses should be preceded and followed by a space.
- c. There should be no spaces between the opening and closing parentheses and the text they frame.

[Example]: (Fig. 1) (P < 0.05) (Smith et al., 2011)

# 6) Italic

- a. Scientific names should be italicized.
- b. Latin words other than scientific names should not be italicized.

Example: in vivo, et al., etc.

# 7) Country names

As a general rule, abbreviated names are not used. When the name of a country is long and the abbreviation is well known, it may be used.

## 8) Citation of chemicals, instruments, and manufacturers

a. The names and locations of manufacturers should be written as follows. When repeating the same manufacturer, omit the city, province/state, and county of origin.

Within the United States: (Manufacturer, city, state abbreviation)

Outside the United States (Manufacturer, city, country)

Only the first letter of each word in the name of the company should be capitalized.

Exception: companies whose name is an acronym.

b. Use common names for chemical substances. If the product name is needed, put it in parentheses.

# 6.4 Bibliographical citations in the text

- All documents cited in the text should be included in a list. Only the sources cited in the text should be listed.
- 2) Indicate citation order in the text with superscript numbers. These should be typed after the period or comma without space. [Example]: ....in the recovery of general health.<sup>2</sup>

# § 7 Acknowledgments

Titles and affiliations should not be abbreviated in the acknowledgments. Start a new line for grant mentions.

# § 8 Conflict of interest

In the case of the absence of conflict of interest, type the following at the end of the main body of text (PMC recommended wording):

The authors declare no conflict of interest.

# § 9 REFERENCES

See 6.4 above for citations in the text.

# 9.1 REFERENCES

1) Order references in the order they appear in the text. Should there be more than 6 authors or editors, use et al. for all the following contributors.

2) Put the PubMed PMID/PubMed Central PMCID at the end of the entry when applicable. For references without the above ID, if they have a Digital Object Identifier (DOI) or publisher item identifier (pii), put it in reference to MEDLINE / PubMed citation models. [P.13,

No.36: Journal article on the Internet]

[Example]

Kitaura T, Chikumi H, Fujiwara H, Okada K, Hayabuchi T, Nakamoto M, et al. Positive predictive value of true bacteremia according to the number of positive culture sets in adult patients. Yanago Acta Med. 2014;57:159-65. PMID: 25901103.

Saarinen T, Fernström L, Brorsson AL, Olinder A.L. Insulin pump therapy is perceived as liberating, but to many it can imply a sense of the diabetes made visible. European Diabetes Nursing. 2014;11:38-42. DOI: 10.1002/edn.246.

# 9.2 Abbreviation of journal names

- 1) Use the abbreviated names used by MEDLINE/PubMed. Do not mix old abbreviations with new ones.
- 2) Do not abbreviate journal names that consist of one word.
- 3) Do not follow each abbreviated word by a period. Use a period after the abbreviated name of the journal.
- 4) The abbreviation for this journal is "Yonago Acta Med."
- 5) For Japanese journals, do not abbreviate the name and write in roman letters. Add "Japanese" at the end. [See P.10, No.5: Languages other than English.] When there is an English abstract, add "Japanese with English abstract" at the end.
- 6) Use the Hepburn system for romanization.
- 7) Refer to Table 5 on how to romanize Japanese journal names.

# 9.3 Reference guideline

Follow the MEDLINE/PubMed reference guidelines. See "Sample references" in the appended "International Committee of Medical Journal Editors (ICMJE): Uniform requirements for manuscripts (URM) submitted to biomedical journals" (P.11-13.)

# § 10 Tables

- 1) Each table should be typed on a separate page with a title and footnote(s). Add consecutive page numbers following REFERENCES.
- 2) Do not use vertical ruled lines. Use as little horizontal ruled lines as possible.
- 3) Tables should fit on a printed page.

Width should be within 1 column width (82 mm) or within 2 column width + column gap (170 mm).

The vertical length should be within 234 mm, including the lines of explanatory text. Do not use landscape orientation.

- 4) Use units with numeral data. Avoid repetition.
- Define abbreviations that are only used in the table in the footnotes. Arrange the definitions in alphabetical order. [Example]: F, female, M, male, NS, not significant.
- 6) Type the footnotes below the data section of the table. Footnote symbols should be used in the order below. Do not use letters or numbers.

\*,  $\dagger$ ,  $\ddagger$ , \$,  $\parallel$ ,  $\P$ , \*\*,  $\dagger$ ,  $\ddagger$ , \$, \$,  $\parallel \parallel$ ,  $\P$ , ... (\*Do not use Japanese fonts.)

7) When comparing significant differences, show the level by the number of asterisks. In this case, start with the dagger symbol for the footnotes other than the indication of significant differences.

[Example]: \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001

8) Use "Table 1, Table 2, Table 3, etc." when referring to tables in the text.

# §11 Legends for figures

- 1) Legends should not be typed above or below each figure. Type all the legends together, separately from the figures. Add consecutive page numbers following References and Table(s).
- 2) As a general rule, the explanation of symbols should be included in the legend and not in the figure itself.
- 3) A short title may be attached to the legend of each figure. Use partial sentences to keep the legend short.
- 4) Define abbreviations that are only used in the figure in the legend. Arrange the definitions in alphabetical order.

5) The description of the staining method should be at the end of the sentence.

[Example]: Fig. 1. . . . (periodic acid-Schiff stain).

6) When the scale marker is within the picture, add text such as "Bar =  $10 \mu m$ " at the end of the legend. Do not show magnification.

[Example]: Fig. 2. . . . (hematoxylin and eosin stain). Bar = 5  $\mu$ m.

# § 12 Figures

1) As a general rule, figures should be submitted in the desired printing size.

The width should be within 1 column width (82 mm) or within 2 column width + column gap (170 mm), and, if possible, be small enough to fit in one column. Height should not exceed 234 mm, including the legend. Do not use landscape orientation unless necessary.

- 2) Each figure should be on a different page. Photo sequences may be on the same page.
- 3) If possible, select symbols from the following to use in figures:  $\circ \times \blacksquare \Box \land \triangle$

Characters should be no smaller than 1.0 mm. Try to avoid using characters smaller than 1.2 mm.

Axis title: Titles for the vertical and horizontal axis should be about 10-12 points.

Scale: Scale numbers should be about 7-8 points with well-balanced overall proportions.

- 4) Use clear pictures only. Crop unnecessary parts as much as possible.
- 5) Include scale markers within photomicrographs. Do not show the original magnification in the legend.
- 6) Label photographic and figure series with numbers or letters.
- 7) Use abbreviated form when referring to the figures in the main text. [Example]: Fig. 1, Figs. 2a and b, Figs. 3–6 Use full word when at the beginning of a paragraph or sentence in the main text. [Example]: Figure 1, Figures 2 and 3

## §13 Abbreviations

## 13.1 General rules

Do not define abbreviations approved for use by this publication.

For the list of approved abbreviations, see Tables 1-4: pp. 9-10.

1) Do not define standard scientific symbols on the first appearance.

[Example]: Write "Na" and not "sodium (Na)."

- 2) Use abbreviations for weights and measurements coming after numbers, even on the first appearance. [Example]: Write "3 mL" not "3 milliliters (mL)."
- 3) Follow the International System of Units (Tables 2 and 3) when writing units. Use "mmHg" for blood pressure measurements.

## 13.2 Usage policy

While abbreviations are often a great tool to save time, refrain from using them as much as possible.

- 1) Do not abbreviate short or relatively short words. Do not abbreviate single words. Spell in full words that are only used once.
- 2) If the citation from the reference contains an acronym, do not cite it as it is. Consider the frequency of use in the manuscript and review the use and non-use of each word.

## **13.3 TITLE and ABSTRACT**

Avoid using abbreviations as much as possible.

## 13.4 Defining

If most readers are familiar with the term, define in parentheses following the first use.

- 1) Use the same abbreviations in the ABSTRACT and the text. Define them in both the ABSTRACT and the TEXT.
- 2) Do not mix the abbreviated and non-abbreviated versions of the same term. Do not spell out an abbreviation you have already defined. See § 10-5) and § 11-4) for usage in tables and figures.
- 3) Keep in mind that the meaning of some chemical symbols changes whether they are italicized or not.
- 4) Follow the rules of Table 4 for statistics symbols.
- 5) Add an "s" to abbreviations to pluralize them. Do not add an "s" to pluralize abbreviations of units. Do not use a period after abbreviations except for periods used per convention such as in Latin.

# 13.5 Author abbreviation list

Add a list of author abbreviations in the singular at the bottom of the first page of the manuscript. List in alphabetical order, not order of appearance. [Do not include abbreviations from Table 1 in the list.]

[Example]

Abbreviations: CSS, cancer specific survival; DFS, disease-free survival; ECUD, extracorporeal urinary diversion

## §14 E-text and online submission

For electronic submissions, attach the document to an e-mail or use an appropriate medium (such as a CD). Send e-mail submissions to <u>yamed@med.tottori-u.ac.jp</u>

For other forms of media, send to Yonago Acta Medica Editorial Office, Tottori University Medical Press, Tottori University Medical Library.

# 14.1 Digital text and tables

1) One software used

If the main text (up to references,) tables, and figure legends have all been created in a word processor (such as Microsoft Word), combine in one document and save under the proper extension.

2) More than one software used

If the main body of the text was typed in a word processor and the tables were created in a spreadsheet software, save the files in their respective software with the proper extension.

Tables created with spreadsheet software such as Excel can be imported in the manuscript (after References) and treated as text. They should fit on one page.

## 14.2 Figures: Digital format

Do not process graphs and linear diagrams as photographs. Submit an editable original version.

- 1) If the file is big, divide it and save it under the proper extension. [Example]: Fig 1.pptx, Fig 2.pptx
- 2) Pictures (black and white, color) may be submitted as jpeg files.
- 3) When adding romaji to a digital photo, create another layer and place it on the lower left.
- 4) When adding a scale marker to a digital photo, create another layer and place it on the lower right. Related articles: P.7 § 11-6), P.7 § 12-5).
- 5) Resolution for digital pictures should be over 260 dpi for black and white and over 300 dpi for color.

<CONTACT> Yonago Acta Medica Editorial Office Tottori University Medical Press 86 Nishi-cho,Yonago City,Tottori Pref., 683-8503, Japan TEL +81-859-38-7541 Email: yamed@med.tottori-u.ac.jp HP: http://www.lib.tottori-u.ac.jp/yam/yam.html

# [Appendices]

# Table 1. List of abbreviations used without defintion in

# Table 2. SI prefixes, prefix symbols and the recommended factors they represent

	List of abbreviations used without defintion in	Factor	Prefix	Symbol	
	Acta Medica	10 <sup>1</sup>	deca	da	
ACTH	adrenocorticotrop(h)ic hormone	10 <sup>2</sup>	hecto	h	
ADP	adenosine 5'-diphosphate	10 <sup>3</sup>	kilo	k	
AMP	adenosine 5'-monophosphate	106	mega	М	
ATP	adenosine 5'-triphosphate	10 <sup>9</sup>	giga	G	
ATPase	adenosine triphosphatase	10 <sup>12</sup>	tera	T	
cAMP	cyclic AMP	10 <sup>15</sup>	peta	P	
cDNA	complementary DNA	10 <sup>18</sup>	exa	E	
DNA	deoxyribonucleic acid	$10^{-1}$			
EDTA	ethylenediaminetetra-acetic acid		deci	d	
EGTA	ethyene glycol bis( $\beta$ -aminoethylether) $N, N, N', N, -$	10-2	centi	с	
	tetraacetic acid	10 <sup>-3</sup>	milli	m	
FAD	flavin adenine dinucleotide	10-6	micro	μ	
FADH <sub>2</sub>	reduced form of FAD	10 <sup>-9</sup>	nano	n	
GDP	guanosine 5'-diphosphate	10 <sup>-12</sup>	pico	р	
GMP	guanosine 5'-monophosphate	10-15	femto	f	
GTP	guanosine 5'-triphosphate	$10^{-18}$	atto	а	
Hb	hemoglobin				
HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid				
LD <sub>50</sub>	median lethal dose (lethal for 50% of test subjects)				
ln, log <sub>e</sub>	natural logarithm	Table 3. SI and relatd units			in medical
log	logarithm	sciences in Yo	nago Acta N	Medica	
mRNA	messenger RNA		LENGTH	m	meter
NAD	nicotinamide-adenine dinucleotide	SU	RFACE AREA		squaremeter
$NAD^+$	oxidized form of NAD		VOLUME		liter
NADH	reduced form of NAD	TE	MPERATURE	°C	degree Celsius
NADP	NAD phosphate	MA	SS (WEIGHT)	g	gram
$NADP^+$	oxidized form of NADP		TIME		day
NADPH	reduced form of NADP			h	hour
PAGE	polyacrylamide gel electrophoresis			min	minute
PCR	polymerase chain reaction		POWER	s W	second watt
pН	negative log of hydrogen-ion concentration		ENERGY		newton
$P_i, PP_i$	inorganic phosphate, inorganic pyrophosphate			J	joule
pK	negative log of dissociation constant		FREQUENCY	Hz	hertz
polyA	poly(adenylic acid) or polyadenylate	CATALYT	TIC ACTIVITY	kat	katal
RNA	ribonucleic acid or ribonucleate		PRESSURE		pascal
		SUBSTANCE CON	ICENTRATION		mole per liter
RNase	ribonuclease	DOGE		M	molar
rRNA	ribosomal RNA		EQUIVALENT ORVED DOSE		sievert
SD	standard deviation	ADS	ACTIVITY	2	gray becquerel
SDS	sodium dodecyl sulfate		EXPOSURE	1	roentgen
SEM, SE	standard error of the mean, standard error	(	OTHER UNITS	-	ampere
Tris	tris(hydroxymethyl)aminomethane			bp	base pair
tRNA	transfer RNA			bpm	beats per minute
UDP	uridine 5'-diphosphate			cpm	counts per minute
UMP	uridine 5'-monophosphate			Da	dalton
UTP	uridine 5'-triphosphate			K	degree absolute
UV	ultraviolet			eq F	equivalent
				F G	farad
				U	gaus

kilobase (pair)

kb

<i>Table 3: continued from the previous page</i>			
	Ω	ohm	
	rpm	revolutions per minute	
	S	Svedberg (10-13 s)	
	V	volt	
THERMODYNAMIC TERMS	$\Delta$ G	Gibbs energy change	
	$\Delta$ H	enthalpy change	
	$\Delta$ S	entropy change	
PHYSICAL AND CHEMICAL	A	absorbance	
QUANTITIES	g	acceleration of gravity	
	D	diffusion coefficient	
	Κ	equilibrium constant	
	$K_m$	Michaelis constant	

s

S

 $[\alpha]^t$ 

 $M_r$ 

 $R_f$ 

sedimentation

specific rotation

retardation factor

sedimentation coefficient

relative molecular mass

## Table 4. Symbols used in statistics

Population	Sample	
symbol	symbol	Explanation
	F	variance ratio [F-test]
$H_{0}$		null hypothesis
N		number of subjects (population or lot size)
	n	number of subjects
	Р	probability of wrongly rejecting the null hypothesis
	R	coefficient of multiple correlation, range of a sample
ρ	r	coefficient of correlation
σ	S	standard deviation
$\sigma^2$	$S^2$	variance
	$S_{ar{x}}$	standard error of the mean
	t	statistic derived in Student <i>t</i> -test
$\bar{X}$	$\bar{x}$	arithmetic mean
	α	probability of a type I error; significant level
	β	probability of a type II error
	$\chi^2$	statistic derived in chi-square test
	V	number of degrees of freedom

Source: Scietific style and format by the CBE manual for authors, editors, and publishers. 6th ed. P. 217, Table 11-13.

# Table 5. Japanese selections from the list of journals indexed for MEDLINE/PubMed users

Arerugi Arukoru Kenkyu To Yakubutsu Ison Eisei Shikenjo Hokoku Fukuoka Igaku Zasshi Gan To Kagaku Ryoho Hinyokika Kiyo Hokkaido Igaku Zasshi Igaku Kenkyu Jikken Dobutsu Kaibogaku Zasshi Kaku Igaku Kansenshogaku Zasshi Kekkaku (Tokyo) Kokubyo Gakkai Zasshi Kokyu To Junkan Kyobu Geka Masui Nihon Eiseigaku Zasshi Nippon Ganka Gakkai Zasshi Nihon Geka Gakkai Zasshi Nihon Geka Hokan Nihon Hinyokika Gakkai Zasshi Nihon Hoigaku Zasshi Nihon Igaku Hoshasen Gakkai Zasshi Nihon Ika Daigaku Zasshi Nihon Jibiinkoka Gakkai Kaiho Nihon Jinzo Gakkai Shi (Tokyo) Nihon Koshu Eisei Zasshi Nihon Kyobu Geka Gakkai Zasshi Nihon Kyobu Shikkan Gakkai Zasshi Nihon Naibunpi Gakkai Zasshi Nihon Naika Gakkai Zasshi Nihon Rai Gakkai Zasshi Nihon Ronen Igakkai Zasshi Nihon Saikingaku Zasshi Nihon Sanka Fujinka Gakkai Zasshi Nihon Seikeigeka Gakkai Zasshi Nihon Seirigaku Zasshi Nihon Shokakibyo Gakkai Zasshi Nihon Yakurigaku Zasshi No Shinkei Geka No To Hattatsu No To Shinkei Rinsho Byori Rinsho Ketsueki Rinsho Shinkeigaku Ryumachi (Tokyo) Sangyo Igaku Sangyo Ika Daigaku Zasshi (Kitakyushu) Seikagaku Seishin Shinkeigaku Zasshi Shinrigaku Kenkyu Tanpakushitsu Kakusan Koso Uirusu (Kyoto) Yakubutsu, Seishin, Kodo Yakugaku Zasshi

# International Committee of Medical Journal Editors (ICMJE) Uniform Requirements for Manusripts (URM) Submitted to Biomedical Journals: Sample references

http://www.nlm.nih.gov/bsd/uniform requirements.html ← Please check this website.

Articles in Journals (see also No. 36. Journal article on the Internet)

#### 1. Standard journal article

List the first six authors followed by et al. (Note: NLM now lists all authors.) Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

As an option, if a journal carries continuous pagination throughout a volume (as many medical journals do) the month and issue number may be omitted. Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

#### More than six authors:

Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, et al. Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury. Brain Res. 2002;935:40-6.

### Optional addition of a database's unique identifier for the citation:

Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002 Jul 25;347:284-7. PMID: 12140307.

Forooghian F, Yeh S, Faia LJ, Nussenblatt RB. Uveitic foveal atrophy: clinical features and associations. Arch Ophthalmol. 2009 Feb;127:179-86. PMID: 19204236; PMCID: PMC2653214.

#### **Optional addition of a clinical trial registration number:**

Trachtenberg F, Maserejian NN, Soncini JA, Hayes C, Tavares M. Does fluoride in compomers prevent future caries in children? J Dent Res. 2009 Mar;88:276-9. PMID: 19329464. ClinicalTrials.gov registration number: NCT00065988.

#### 2. Organization as author

- Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. Hypertension. 2002;40:679-86.
- **3. Both personal authors and organization as author** (List all as they appear in the byline.)
- Vallancien G, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol. 2003;169:2257-61.
- Margulies EH, Blanchette M; NISC Comparative Sequencing Program, Haussler D, Green ED. Identification and characterization of multi-species conserved sequences. Genome Res. 2003 Dec;13:2507-18.

#### 4. No author given

• 21st century heart solution may have a sting in the tail. BMJ. 2002;325(7357):184.

#### 5. Article not in English

• Ellingsen AE, Wilhelmsen I. Sykdomsangst blant medisin- og jusstudenter. Tidsskr Nor Laegeforen. 2002;122:785-7. Norwegian.

#### **Optional translation of article title:**

• Ellingsen AE, Wilhelmsen I. [Disease anxiety among medical students and law students]. Tidsskr Nor Laegeforen. 2002 20;122:785-7. Norwegian.

#### 6. Volume with supplement

• Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with shortand long-term use for treatment of migraine and in comparison with sumatriptan. Headache. 2002;42 Suppl 2:S93-9.

#### 7. Issue with supplement

• Glauser TA. Integrating clinical trial data into clinical practice. Neurology. 2002;58(12 Suppl 7):S6-12.

#### 8. Volume with part

• Abend SM, Kulish N. The psychoanalytic method from an epistemological viewpoint. Int J Psychoanal. 2002;83(Pt 2):491-5.

#### 9. Issue with part

• Ahrar K, Madoff DC, Gupta S, Wallace MJ, Price RE, Wright KC. Development of a large animal model for lung tumors. J Vasc Interv Radiol. 2002;13(9 Pt 1):923-8.

#### **10. Issue with no volume**

• Banit DM, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. Clin Orthop. 2002;(401):230-8.

#### 11. No volume or issue

• Outreach: bringing HIV-positive individuals into care. HRSA Careaction. 2002 Jun:1-6.

### ICMJE URM: Sample references, continued from the previous page

#### 12. Pagination in roman numerals

•Chadwick R, Schuklenk U. The politics of ethical consensus finding. Bioethics. 2002;16(2):iii-v.

#### 13. Type of article indicated as needed

- Tor M, Turker H. International approaches to the prescription of long-term oxygen therapy [letter]. Eur Respir J. 2002;20(1):242.
- Lofwall MR, Strain EC, Brooner RK, Kindbom KA, Bigelow GE. Characteristics of older methadone maintenance (MM) patients [abstract]. Drug Alcohol Depend. 2002;66 Suppl 1:S105.

#### 14. Article containing retraction

• Feifel D, Moutier CY, Perry W. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. J Clin Psychiatry. 2002;63(2):169. Retraction of: Feifel D, Moutier CY, Perry W. J Clin Psychiatry. 2000;61(12):909-11.

#### Article containing a partial retraction: [Added 12 May 2009]

 Starkman JS, Wolder CE, Gomelsky A, Scarpero HM, Dmochowski RR. Voiding dysfunction after removal of eroded slings. J Urol. 2006 Dec;176(6 Pt 1):2749. Partial retraction of: Starkman JS, Wolter C, Gomelsky A, Scarpero HM, Dmochowski RR. J Urol. 2006 Sep;176(3):1040-4.

#### 15. Article retracted

• Feifel D, Moutier CY, Perry W. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. J Clin Psychiatry. 2000;61(12):909-11. Retraction in: Feifel D, Moutier CY, Perry W. J Clin Psychiatry. 2002;63(2):169.

#### Article partially retracted: [Added 12 May 2009]

• Starkman JS, Wolter C, Gomelsky A, Scarpero HM, Dmochowski RR. Voiding dysfunction following removal of eroded synthetic mid urethral slings. J Urol. 2006 Sep;176(3):1040-4. Partial retraction in: Starkman JS, Wolder CE, Gomelsky A, Scarpero HM, Dmochowski RR. J Urol. 2006 Dec;176(6 Pt 1):2749.

#### 16. Article republished with corrections

• Mansharamani M, Chilton BS. The reproductive importance of P-type ATPases. Mol Cell Endocrinol. 2002;188(1-2):22-5. Corrected and republished from: Mol Cell Endocrinol. 2001;183(1-2):123-6.

#### 17. Article with published erratum

• Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther. 2000;22(10):1151-68; discussion 1149-50. Erratum in: Clin Ther. 2001;23(2):309.

#### 18. Article published electronically ahead of the print version

• Yu WM, Hawley TS, Hawley RG, Qu CK. Immortalization of yolk sac-derived precursor cells. Blood. 2002 Nov 15;100(10):3828-31. Epub 2002 Jul 5.

## **Books and Other Monographs**

#### 19. Personal author(s)

• Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Medical microbiology. 4th ed. St. Louis: Mosby; 2002.

#### 20. Editor(s), compiler(s) as author

• Gilstrap LC 3rd, Cunningham FG, VanDorsten JP, editors. Operative obstetrics. 2nd ed. New York: McGraw-Hill; 2002.

#### 21. Author(s) and editor(s)

• Breedlove GK, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wieczorek RR, editor. White Plains (NY): March of Dimes Education Services; 2001.

#### 22. Organization(s) as author

• Advanced Life Support Group. Acute medical emergencies: the practical approach. London: BMJ Books; 2001. 454 p.

- American Occupational Therapy Association, Ad Hoc Committee on Occupational Therapy Manpower. Occupational therapy manpower: a plan for progress. Rockville (MD): The Association; 1985 Apr. 84 p.
- National Lawyer's Guild AIDs Network (US); National Gay Rights Advocates (US). AIDS practice manual: a legal and educational guide. 2nd ed. San Francisco: The Network; 1988.

#### 23. Chapter in a book

• Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw-Hill; 2002. p. 93-113.

#### 24. Conference proceedings

• Harnden P, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ Cell Tumour Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer; 2002.

#### 25. Conference paper

• Christensen S, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer; 2002. p. 182-91.

#### 26. Scientific or technical report

- Issued by funding/sponsoring agency:
- Yen GG (Oklahoma State University, School of Electrical and Computer Engineering, Stillwater, OK). Health monitoring on vibration signatures. Final report. Arlington (VA): Air Force Office of Scientific Research (US), Air Force Research Laboratory; 2002 Feb. Report No.: AFRLSRBLTR020123. Contract No.: F496209810049.

## Issued by performing agency:

 Russell ML, Goth-Goldstein R, Apte MG, Fisk WJ. Method for measuring the size distribution of airborne Rhinovirus. Berkeley (CA): Lawrence Berkeley National Laboratory, Environmental Energy Technologies Division; 2002 Jan. Report No.: LBNL49574. Contract No.: DEAC0376SF00098. Sponsored by the Department of Energy.

#### 27. Dissertation

• Borkowski MM. Infant sleep and feeding: a telephone survey of Hispanic Americans [dissertation]. Mount Pleasant (MI): Central Michigan University; 2002.

#### 28. Patent

• Pagedas AC, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1.

## **Other Published Material**

#### 29. Newspaper article

• Tynan T. Medical improvements lower homicide rate: study sees drop in assault rate. The Washington Post. 2002 Aug 12;Sect. A:2 (col. 4).

#### **30. Audiovisual material**

• Chason KW, Sallustio S. Hospital preparedness for bioterrorism [videocassette]. Secaucus (NJ): Network for Continuing Medical Education; 2002.

### 31. Legal Material

#### **Public law:**

• Veterans Hearing Loss Compensation Act of 2002, Pub. L. No. 107-9, 115 Stat. 11 (May 24, 2001).

#### Unenacted bill:

• Healthy Children Learn Act, S. 1012, 107th Cong., 1st Sess. (2001).

#### **Code of Federal Regulations:**

• Cardiopulmonary Bypass Intracardiac Suction Control, 21 C.F.R. Sect. 870.4430 (2002).

#### Hearing:

• Arsenic in Drinking Water: An Update on the Science, Benefits and Cost: Hearing Before the Subcomm. on Environment, Technology and Standards of the House Comm. on Science, 107th Cong., 1st Sess. (Oct. 4, 2001).

#### 32. Map

• Pratt B, Flick P, Vynne C, cartographers. Biodiversity hotspots [map]. Washington: Conservation International; 2000.

#### 33. Dictionary and similar references

• Dorland's illustrated medical dictionary. 29th ed. Philadelphia: W.B. Saunders; 2000. Filamin; p. 675.

### **Unpublished Material**

- **34. In press or Forthcoming** (Note: NLM prefers "Forthcoming" rather than "In press" because not all items will be printed.)
- Tian D, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. Proc Natl Acad Sci U S A. Forthcoming 2002.

### **Electronic Material**

#### 35. CD-ROM

 Anderson SC, Poulsen KB. Anderson's electronic atlas of hematology [CD-ROM]. Philadelphia: Lippincott Williams & Wilkins; 2002.

#### 36. Journal article on the Internet

- Abood S. Quality improvement initiative in nursing homes: the ANA acts in an advisory role. Am J Nurs [Internet]. 2002 Jun [cited 2002 Aug 12];102(6):[about 1 p.]. Available from: http://www.nursingworld.org/AJN/2002/june/Wawatch.htmArticle
- Optional presentation (omits bracketed phrase that qualifies the journal title abbreviation):
- Abood S. Quality improvement initiative in nursing homes: the ANA acts in an advisory role. Am J Nurs. 2002 Jun [cited 2002 Aug 12];102(6):[about 1 p.]. Available from: http://www.nursingworld.org/AJN/2002/june/Wawatch.htmArticle
- Article published on the Internet ahead of the print version: See # 18.

#### **Optional formats used by NLM in MEDLINE/PubMed:**

- Article with document number in place of traditional pagination:
- Williams JS, Brown SM, Conlin PR. Videos in clinical medicine. Blood-pressure measurement. N Engl J Med. 2009 Jan 29;360(5):e6. PMID: 19179309.

#### Article with a Digital Object Identifier (DOI):

- Zhang M, Holman CD, Price SD, Sanfilippo FM, Preen DB, Bulsara MK. Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ. 2009 Jan 7;338:a2752. doi: 10.1136/bmj.a2752. PMID: 19129307; PMCID: PMC2615549.
- Article with unique publisher item identifier (pii) in place of traditional pagination or DOI:
- Tegnell A, Dillner J, Andrae B. Introduction of human papillomavirus (HPV) vaccination in Sweden. Euro Surveill. 2009 Feb 12;14(6). pii: 19119. PMID: 19215721.

#### 37. Monograph on the Internet

• Foley KM, Gelband H, editors. Improving palliative care for cancer [Internet]. Washington: National Academy Press; 2001 [cited 2002 Jul 9]. Available from: http://www.nap.edu/ books/0309074029/html/.

#### 38. Homepage/Web site

• Cancer-Pain.org [Internet]. New York: Association of Cancer Online Resources, Inc.; c2000-01 [updated 2002 May 16; cited 2002 Jul 9]. Available from: http://www.cancer-pain.org/.

#### **39.** Part of a homepage/Web site

American Medical Association [Internet]. Chicago: The Association; c1995-2002 [updated 2001 Aug 23; cited 2002 Aug 12]. AMA Office of Group Practice Liaison; [about 2 screens]. Available from: http://www.ama-assn.org/ama/pub/catego-ry/1736.html

#### 40. Database on the Internet

#### **Open database:**

• Who's Certified [Internet]. Evanston (IL): The American Board of Medical Specialists. c2000 - [cited 2001 Mar 8]. Available from: http://www.abms.org/newsearch.asp

#### **Closed database:**

 Jablonski S. Online Multiple Congenital Anomaly/Mental Retardation (MCA/MR) Syndromes [Internet]. Bethesda (MD): National Library of Medicine (US); c1999 [updated 2001 Nov 20; cited 2002 Aug 12]. Available from: http://www.nlm.nih. gov/archive//20061212/mesh/jablonski/syndrome\_title.html

#### 41. Part of a database on the Internet

• MeSH Browser [Internet]. Bethesda (MD): National Library of Medicine (US); 2002 - . Meta-analysis [cited 2008 Jul 24]; [about 2 p.]. Available from: http://www.nlm.nih.gov/cgi/ mesh/2008/MB\_cgi?mode=&index=16408&view=concept MeSH Unique ID: D017418.

#### 42. Blogs [Added 12 May 2009]

- Holt M. The Health Care Blog [Internet]. San Francisco: Matthew Holt. 2003 Oct - [cited 2009 Feb 13]. Available from: http://www.thehealthcareblog.com/the\_health\_care\_blog/.
- KidneyNotes.com [Internet]. New York: KidneyNotes. c2006 [cited 2009 Feb 13]. Available from: http://www.kidneynotes. com/.
- Wall Street Journal. HEALTH BLOG: WSJ's blog on health and the business of health [Internet]. Hensley S, editor. New York: Dow Jones & Company, Inc. c2007 - [cited 2009 Feb 13]. Available from: http://blogs.wsj.com/health/.

#### **Contribution to a blog:**

- Mantone J. Head trauma haunts many, researchers say. 2008 Jan 29 [cited 2009 Feb 13]. In: Wall Street Journal. HEALTH BLOG [Internet]. New York: Dow Jones & Company, Inc. c2008 - . [about 1 screen]. Available from: http://blogs.wsj. com/health/2008/01/29/head-trauma-haunts-many-researcherssay/.
- Campbell A. Diabetes and alcohol: do the two mix? (Part 2). 2008 Jan 28 [cited 2009 Feb 13]. In: Diabetes Self-Management Blog [Internet]. New York: Diabetes Self-Management. [2006 Aug 14] - . 2 p. Available from: http://www.diabetesselfmanagement.com/blog/Amy\_Campbell/Diabetes\_and\_Alcohol\_ Do\_the\_Two\_Mix\_Part\_2
- Reider J. Docnotes: Health, Technology, Family Medicine and other observations [Internet]. [place unknown]: Jacob Reider. 1999 - . CRP again ...; 2004 Apr 2 [cited 2009 Feb 13]; [about 1 screen]. Available from: http://www.docnotes.com/2004/04/ crp-again.html

## **ICMJE Form for Disclosure of Potential Conflicts of Interest**

http://www.icmje.org/conflicts-of-interest/ 
Please conduct a self-check for the status of conflicts of interest (COI) via this website.
The abstract form is below

#### Section 1. Identifying information

- 1. Given Name (First Name)
- 2. Surname (Last Name)
- 3. Date
- 4. Are you the corresponding author?  $\Box$  Yes  $\Box$  No
- 5. Mabuscript Title
- 6. Manuscript Identifying Number (if you know it)

#### Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest?  $\Box$  Yes  $\Box$  No

# Section 3. Relevant financial activities outside the submitted work

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication. Are there any relevant conflicts of interest?  $\Box$  Yes  $\Box$  No

#### Section 4. Interectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?  $\Box$  Yes  $\Box$  No

#### Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- ☐ Yes, the following relationships/conditions/circumstances are present (explain below):
- □ No other relationships/conditions/circumstances that present a potential conflict of interest

#### Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Generate Disclosure Statement

# **Code of Ethics**

- If the content of the dissertation is a clinical study, informed consent from the subject and approval of the research plan by the Institutional Ethics Committee (or equivalent) have been obtained, the authorization number must be included in the text. Also, it should be stated in the text that research requiring the approval of the ethics committee, such as observational research (information, samples, etc.), has been approved. Also, include the authorization number in the text. However, in the case of a simple patient report, the number is not necessary unless the said report includes statistical processing, etc. In the case of animal experiments, include in the text the Animal Care and Use Committee's authorization number, which confirms that the research is compliant with the guidelines.
- If the content of the article is based on a clinical trial, it must be registered in a clinical trial registration system that meets the criteria of the International Committee of Medical Journal Editors (ICMJE) such as UMIN-CTR. Specify in the text that registration has been completed, and include the authorization number in the text.
- If research included administration of an unapproved drug or unapproved medical technology, it should be stated in the text. Also, when using drugs that may cause adverse side effects, such as antineoplastic drugs, indicate in the text, together with the authorization number, that they have been reviewed by an appropriate ethics committee.
- Comply with the Personal Information Protection Act when handling personal information. Especially in case reports and clinical research, describe the clinical course so that it may be identified without specifying the name, date of birth, and dates such as the date of implementation to ensure that individuals are not identified and their privacy is protected.

#### <sup>添え状</sup> 編集長への covering letter について

原稿はオンライン投稿\*で受け付けます.投稿時・改定時に編集長宛のカバーレターをメール本文へお書き下さい. 特殊フォント使用の場合は、ワード書類などとして添付下さい.できれば和文でお書き下さい[英文でもよい]. \*原稿の電子テキスト(本文・図・表)を電子メールへ添付し編集担当へ送信する.編集委員長宛とする.

以下の例は学位申請予定論文の場合です.

学位申請予定論文は、投稿者が査読者を2名指名することができます.主査、副査を査読者として指名すること も可能です.ただし、必ずしも指名者が査読者に決定するとは限りません.また、投稿者が査読者の指名を希望 しない場合は、編集委員会にて選定を行います.(副論文の場合、査読者の指名はできません.)

[ご注意] 共著者へは査読依頼できない事になっています.
 共著者は主査にはなれません.共著者は副査にはなれます.
 当誌では著者と同じ所属の研究者へは原則として査読依頼致しません.
 詳細は学務課へお尋ね下さい.

#### 投稿時

 Yonago Acta Medica 編集長

 ○○教授殿

 挨拶など(簡単に)
 論題、著者名を明記する.
 論文の新知見について簡潔に記す.
 COIの有無を記す.
 COIの有無を記す.
 (学位審査用の申請の場合)
 当論文は、××の学位論文として申請する予定ですので 査読者として主査▲▲教授並びに副査◆◆教授を希望します.
 または
 当論文は、××の学位論文として申請する予定ですので 査読者として副査★★教授と◆◆教授を希望します.

 主査
 ▲▲教授(・・分野)
 副査

 副査
 ◆教授(・・分野)

日 付 所 属

xx(著者名)

改訂時 査読者 2 名 (Referees A and B) からの査読回答書に対する著者のコメントを 編集長宛にまとめる.

	コスノドで「柵未及死によこのる」
Yonago Acta Medica 編集長 ○○教授殿	
挨拶など (簡単に) 先日投稿いたしました論文 "A Study on" について査読回答書を 頂きましたので、指示に従い改訂しました .	
査読回答へ番号を振り、 番号順に point-by-point response で 返答 / 修正を書く	モニタ上で原稿チェックをするように なっていますので
改訂稿を再投稿いたします.改訂稿では、 <mark>Referee A 回答に対する返答 / 修正を赤色テキスト</mark> 、 Referee B回答に対する返答 / 修正を青色テキストと色分けしています. 宜しくお願いします・・など.	改訂箇所等を彩色して下さい
日 付 所 属 ××(著者名)	2220